Spots Global Cancer Trial Database for A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
Official Title: An Open-Label Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Multiple Myeloma
Study ID: NCT00096837
Conditions
Interventions
Study Description
Brief Summary: The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
